自行注射免疫疗法：产品、疗法、市场和策略

Self-administered Injectable Immune Therapeutics, Products, Therapeutics, Markets & Strategies

出版日期: 2024年01月17日 | 出版商:

Greystone Research Associates | 英文 250 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

在抗体药物及其候选药物激增的推动下，生物製剂在开发管道和临床试验中继续超过所有其他新化学实体。这种从小分子药物的转变正在为药物开发商、医疗器材设计师、包装商甚至药物行销人员创造商机。

由于生物製剂通常针对慢性疾病，因此必须制定长期使用的剂量策略和治疗方案，并且往往受到与医疗状况直接相关的潜在限制，必须制定供某些患者自行注射的方案。未来五年，随着药物开发商应对越来越多的慢性病患者的需求，包装从一次性和多用途小瓶转向预充式註射器的转变将会加速。抗体、荷尔蒙和其他生物製剂的强大生理作用也增加了对安全性和合规性的需求。

本报告对全球自给药注射免疫治疗市场进行了分析，并概述了产品、主要类型、市场基本结构、主要驱动和限制因素以及主要公司的未来前景（截至2028年）。开发策略及其影响因素，自用注射免疫治疗药物的开发和製造生态系统，以及未来产品选择的关键经济、技术和监管因素。

贴片泵浦
大容量穿戴装置
穿戴式产品分析
Libertas (Becton Dickinson)
Patch Pump (Sensile Medical)
SmartDose (West Pharmaceuticals)
Neulasta OnPro Injector (Insulet/Amgen)
YpsoDose (Ypsomed)
电子半一次性产品
E3D Patch Pump (Elcam)
一次性机械产品
enFuse (Enable Injections)
专用设备
sc2Wear Infusor (scPharmaceuticals)
PatchPump (SteadyMed)

新技术

无线数据
重点治疗领域分析
过敏反应/措施
自身免疫性疾病
类风湿关节炎
银屑病
多发性硬化症
紧急医疗护理
肝炎
造血作用
激素
骨质疏鬆症

市场因素

监管问题
设备品牌
患者依从性和易用性
卫生经济学
生物药元素
供货时的包装
配方要素
生物给药生态系统
技术要素
竞争格局

简介目录

Therapeutics is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for therapeutic biological drugs. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Engineered Therapeutics for Refractory Conditions

Led by the proliferation of antibody-based drugs and candidates, biological drugs as a class continue to outpace all other NCEs in development pipelines and clinical trials. This shift away from small molecule drugs is creating opportunities for drug developers, device designers, packagers and - ultimately - pharmaceutical marketers.

Because biological drugs most often target chronic conditions, dosing strategies and treatment protocols must be developed for long-term use, often for self-administration by patients who may have limitations directly related to their condition. The shift in as-supplied packaging from single and multi-use vials to prefilled injection devices will accelerate over the next five years as drug developers move to empower an increasing number of chronically ill patients. The powerful physiological effects of antibodies, hormones and other biological drugs also increase the need for safety and compliance.

What You Will Learn:

What are the market factors that define the therapeutic injectable immune disease market?

What are the major factors driving product development strategies within biologicals drug development organizations to 2028?

How does the availability of patient support resources influence prescribing decisions for immune drugs?

How important are drug developer-formulation technologist relationships in therapeutic market segments?

What is the current state of the global self-administered immune therapeutics development and manufacturing ecosystem?

What are the significant economic, technological, and regulatory factors affecting the selection criteria for self-administered immune therapeutics to 2028?